HGH Fragment 176-191: The Lipolytic Domain of Human Growth Hormone

HGH Fragment 176-191 is a synthetic 16-amino-acid peptide corresponding to the C-terminal region of human growth hormone (hGH), identified in structure-activity research as the domain that carries the hormone's lipolytic activity independent of the classical GH receptor. Research on this fragment predates — and provided the structural rationale for — the later development of modified analogs such as AOD-9604.

This article focuses on the parent unmodified sequence: how the C-terminal domain was mapped, what biochemical characterization established its activity, and why the 176-191 stretch retains lipid-metabolism behavior when most of the intact hormone does not. References throughout point to the foundational domain-mapping literature rather than the later modified-analog studies.

Key Takeaways

• HGH Fragment 176-191 corresponds to the C-terminal 16 residues of the 191-amino-acid human growth hormone molecule.
• Synthesis and activity studies by Wade, Ng, Bornstein and colleagues in the late 1970s first demonstrated that short C-terminal fragments retained metabolic activity of the intact hormone.
• Wu and Ng (1993) showed that the synthetic hGH 177-191 sequence carried antilipogenic activity equivalent to, and at equimolar concentrations more potent than, the intact hGH molecule.
• Receptor-binding studies established that the C-terminal fragment does not engage the classical GH receptor, separating lipid-metabolism activity from somatogenic (growth-promoting) signaling.
• AOD-9604 is a later modified derivative of this same domain, engineered for improved enzymatic stability during oral administration in preclinical models.

Background: Human Growth Hormone as a Multi-Domain Molecule

Human growth hormone is a 191-amino-acid, four-helix-bundle protein produced by the anterior pituitary. Its biological activity has been described across several distinct phenomena — stimulation of linear growth through the classical GH receptor and IGF-I axis, modulation of carbohydrate metabolism, and mobilization of lipids from adipose tissue. A central question for endocrine biochemistry through the 1970s and 1980s was whether these phenomena reflected a single integrated receptor interaction or whether separable structural domains of the hormone were responsible for different biological readouts.

Early structure-activity work focused on proteolytic and synthetic fragments of the hGH molecule. By treating hGH with selective proteases and testing the resulting fragments in metabolic assays, researchers observed that certain activities of the intact hormone were retained in discrete fragments while others were lost. This fragmentation approach established a working model in which the lipolytic and antilipogenic activities of hGH could be mapped to the C-terminal region of the molecule, while the somatogenic (growth-promoting) activity required the intact four-helix structure for GH receptor engagement.

The crystal structure of the hGH–hGH receptor complex, solved by de Vos, Ultsch and Kossiakoff (1992), confirmed that the receptor-binding determinants of hGH are distributed across helix 1, helix 4, and the loop connecting helices 1 and 2 — structural elements outside the C-terminal 176-191 stretch. This provided a structural rationale for the observation that C-terminal fragments retain lipid-metabolism activity without binding the GH receptor.

Identification of the Lipolytic Domain

The first systematic mapping of metabolic activity to the C-terminal region was published by Ng and Bornstein (1978) in the American Journal of Physiology. The investigators synthesized a series of overlapping peptides spanning residues 172-191, 176-191, 177-191, 178-191, 179-191, and 180-191 of the hGH sequence and tested each fragment for metabolic activity in normal rats. Four of the synthesized peptides — hGH 172-191, 176-191, 177-191, and 178-191 — produced a measurable rise in blood glucose and a more sustained rise in plasma insulin, while the shorter fragments showed diminished activity. The 178-191 peptide further reduced insulin sensitivity in intravenous insulin tolerance testing.

Wade, Pullin, Ng, and Bornstein (1979), publishing in the International Journal of Peptide and Protein Research, reported the solid-phase synthesis and biological activity of hGH-(177-191), hGH-(178-191), and hGH-(179-191). Their work established that the C-terminal 15-residue peptide could be produced to high purity by solid-phase synthesis and retained diabetogenic activity when compared to the intact hormone in rat models. These syntheses formed the chemical foundation for all subsequent work on the 176-191 domain.

Taken together, the Ng group's 1978-1979 papers demonstrated that:

• The metabolic activities of hGH could be reproduced by a short synthetic peptide corresponding to the C-terminal region.
• Truncations shorter than residue 178 progressively lost activity, defining a minimal active domain near 176-191.
• The synthesized fragments could be produced in research-grade quantities for structure-activity work.

Biochemical Characterization of the 176-191 Fragment

The antilipogenic activity of the C-terminal fragment was characterized in detail by Wu and Ng (1993), published in Biochemistry and Molecular Biology International. The investigators tested synthetic hGH 177-191 (sequence Leu-Arg-Ile-Val-Gln-Cys-Arg-Val-Ser-Glu-Gly-Ser-Cys-Gly-Phe) in isolated rat adipose tissue preparations and reported that the synthetic peptide inhibited lipogenesis with activity equivalent to the intact hGH molecule. At equimolar concentrations the synthetic peptide was more potent than full-length hGH, a finding the authors interpreted as evidence that accessibility of the active domain is restricted in the folded intact hormone.

A companion study by Wu and Ng (1993), published in the same journal, examined the effect of hGH 177-191 on glucose transport in adipocytes isolated from genetically obese Zucker rats. The synthetic peptide induced a reduction in both basal and insulin-stimulated 2-deoxyglucose uptake in isolated adipocytes, providing a mechanistic link between antilipogenic activity and glucose-handling at the adipocyte level. The effect was again more potent on an equimolar basis than the intact hormone.

Natera, Jiang, and Ng (1994), publishing in the same journal, extended these in vitro observations to a chronic in vivo protocol. Obese mice receiving chronic treatment with synthetic hGH 177-191 showed a reduction in cumulative body weight gain and a decrease in adipose tissue mass relative to controls, with adipose-tissue lipogenesis significantly inhibited in treated animals.

Ng and colleagues (2000), publishing in the Journal of Molecular Endocrinology, reported a mechanistic characterization of the synthetic fragment (designated AOD9401 in that publication). In isolated rat adipose tissue, the fragment stimulated hormone-sensitive lipase and inhibited acetyl-CoA carboxylase — the two enzymatic hinge points of the lipolysis-versus-lipogenesis balance — in a manner parallel to the intact hGH molecule. Chronic treatment of obese Zucker rats over 20 days reduced body-weight gain and decreased average adipocyte cell size from approximately 110 to 80 micrometers in diameter.

Mechanism Independence from the GH Receptor

A defining biochemical feature of the 176-191 fragment is that it does not interact with the classical growth hormone receptor. Receptor-binding assays performed on the synthetic fragment consistently reported no measurable affinity for the GH receptor, distinguishing its activity from that of the intact hormone.

This dissociation is consistent with the structural biology of the hGH–receptor complex characterized by de Vos, Ultsch, and Kossiakoff (1992) in Science, and extended by Chen and colleagues in subsequent mutational work. The GH-receptor binding surface of intact hGH is constructed from residues in helices 1 and 4 and in the loop between helices 1 and 2 — regions of the molecule that are absent from the 176-191 fragment. The C-terminal stretch contributes to the overall fold of the intact hormone but does not itself carry GH-receptor contact residues.

The practical consequence for research is that the fragment allows lipid-metabolism effects of the C-terminal domain to be studied in isolation from the somatogenic and IGF-I-stimulatory effects that accompany intact hGH administration. Ng and colleagues (2000) reported that chronic treatment with the synthetic fragment did not induce the insulin resistance or glucose intolerance observed with chronic intact hGH administration under comparable protocols, consistent with the absence of GH-receptor-mediated signaling.

For broader context on how the intact growth hormone molecule affects adipose-tissue metabolism through the classical receptor, Kopchick and colleagues have published extensive reviews summarizing the downstream signaling. Researchers working with the C-terminal fragment typically position it as a tool for isolating the receptor-independent component of hGH's adipose-tissue activity, rather than as a substitute for studying intact hGH signaling.

Distinction from AOD-9604

AOD-9604 is a modified derivative of the parent 176-191 sequence in which the C-terminal tyrosine residue is substituted with phenylalanine and a tyrosine is added at the N-terminus. The substitution was designed by Metabolic Pharmaceuticals Ltd. and collaborators at Monash University to address enzymatic-stability limitations that constrained oral administration of the unmodified fragment in preclinical models. The modification was intended to preserve the lipolytic activity of the parent domain while improving resistance to degradation.

AOD-9604 has been the subject of its own body of preclinical and clinical investigation, including beta-3 adrenergic receptor knockout studies and human clinical trials. Readers interested in the AOD-9604 research program can consult the AOD-9604 research summary, which covers that literature in detail.

The distinction that matters for structure-activity research is that the unmodified hGH 176-191 fragment represents the native C-terminal sequence of hGH, while AOD-9604 is an engineered analog. Structure-activity observations made on one do not automatically transfer to the other — metabolic stability, pharmacokinetic behavior, and receptor-interaction profiles can differ between the two peptides.

Laboratory Handling Notes

HGH Fragment 176-191 is supplied as a lyophilized powder. Published research protocols have stored the lyophilized peptide at -20 degrees Celsius prior to use, with reconstitution in sterile bacteriostatic water for research applications. The disulfide bridge between the two cysteine residues in the 16-amino-acid sequence contributes to the fragment's conformation; research-grade material is verified by HPLC for purity and by mass spectrometry for identity, with the Certificate of Analysis (COA) documenting both parameters. Researchers can consult the peptide reconstitution guide for handling protocols and how to read a peptide COA for interpreting batch-level documentation.

All findings discussed in this article are derived from peer-reviewed preclinical investigations. HGH Fragment 176-191 is supplied for research applications only.

References

1. Ng, F.M., and Bornstein, J. "Hyperglycemic action of synthetic C-terminal fragments of human growth hormone." American Journal of Physiology 234.5 (1978): E521-E526. PubMed: 206156
2. Wade, J.D., Pullin, C.O., Ng, F.M., and Bornstein, J. "Diabetogenic action of human growth hormone: synthesis and activity of C-terminal fragments." International Journal of Peptide and Protein Research 13.4 (1979): 388-396.
3. Wu, Z., and Ng, F.M. "Antilipogenic action of synthetic C-terminal sequence 177-191 of human growth hormone." Biochemistry and Molecular Biology International 30.1 (1993): 187-196. PubMed: 8358331
4. Wu, Z., and Ng, F.M. "Effect of an antilipogenic fragment of human growth hormone on glucose transport in rat adipocytes." Biochemistry and Molecular Biology International 31.3 (1993): 543-552. PubMed: 8118430
5. Natera, S.H.A., Jiang, W.J., and Ng, F.M. "Reduction of cumulative body weight gain and adipose tissue mass in obese mice: response to chronic treatment with synthetic hGH 177-191 peptide." Biochemistry and Molecular Biology International 33.6 (1994): 1011-1021. PubMed: 7987248
6. Ng, F.M., Sun, J., Sharma, L., Libinaka, R., Jiang, W.J., and Gianello, R. "Molecular and cellular actions of a structural domain of human growth hormone (AOD9401) on lipid metabolism in Zucker fatty rats." Journal of Molecular Endocrinology 25.3 (2000): 287-298. PubMed: 11116208
7. de Vos, A.M., Ultsch, M., and Kossiakoff, A.A. "Human growth hormone and extracellular domain of its receptor: crystal structure of the complex." Science 255.5042 (1992): 306-312.
8. Kopchick, J.J., Berryman, D.E., Puri, V., Lee, K.Y., and Jorgensen, J.O.L. "The effects of growth hormone on adipose tissue: old observations, new mechanisms." Nature Reviews Endocrinology 16.3 (2020): 135-146. PubMed: 31780780

Related Resources

• HGH Fragment 176-191 — product page, COA verified
• Growth hormone research peptides — category hub
• AOD-9604: Modified Growth Hormone Fragment Research
• Peptide reconstitution guide
• How to read a peptide Certificate of Analysis

---

For research purposes only. Not for human consumption. This product is not a drug, food, or cosmetic and is not intended to diagnose, treat, cure, or prevent any disease. Must be 18+ to purchase. PinPoint Peptides is not a pharmacy and does not provide medical advice.